When will Beam Therapeutics submit a BLA for Risto-cel?
As of Tue, 20 Oct 2026 11:11:57 UTC, Kalshi traders price before April 2027 (73.0%), before 2027 (52.0%), before December (32.0%). The market has $30K in volume and closes on Thu, 01 Apr 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| before April 2027 | 73.0% | 73.0¢ | 27.0¢ |
| before 2027 | 52.0% | 52.0¢ | 48.0¢ |
| before December | 32.0% | 32.0¢ | 68.0¢ |
| before November | 3.0% | 3.0¢ | 97.0¢ |
| before October | 3.0% | 3.0¢ | 97.0¢ |
Market details
- Venue: Kalshi
- Volume: $30K
- Liquidity: $30K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for before April 2027:
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
Sources
Related markets
- When will the FDA reclassify BPC-157 to Category 1?
- Will the U.S. confirm that aliens exist?
- Best AI at the end of 2026?
- When will Anthropic release Mythos?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases this year?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.